| Date | Title | Description |
| 01.11.2024 | Revolutionizing Cancer Treatment: The Promise of SUPLEXA | In the battle against cancer, a new weapon has emerged from the laboratories of Australia. SUPLEXA, a groundbreaking treatment, is turning the tide by harnessing the power of the patient’s own immune cells. This innovative approach is not j... |
| 01.11.2024 | The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 39th Annual Meeting | SITC 2024 Logo
The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all of the Late-breaking Abstr... |
| 31.10.2024 | Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients | ADELAIDE, Australia and BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient's ow... |
| 31.10.2024 | Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough | BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer.
&qu... |
| 30.10.2024 | Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 39th Annual Meeting | SITC 2024 Logo
The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2024, more than 1,500, including a record-breaking number of clinical based Late-breaking Abstracts. SITC is proud to ann... |
| 14.08.2024 | Halda Therapeutics: A New Dawn in Cancer Treatment | In the relentless battle against cancer, drug resistance often feels like a formidable fortress. Standard treatments, while effective for many, frequently fall short as tumors evolve and adapt. This is where Halda Therapeutics enters the fr... |
| 13.08.2024 | SITC Announces Fireside Chat with Dr. Kim Rathmell and Dr. Leisha Emens at its 39th Annual Meeting | SITC 2024 logo
The Society for Immunotherapy of Cancer (SITC) has the pleasure of hosting a prestigious fireside chat featuring two distinguished figures in the field of cancer and immuno-oncology: Kim Rathmell, MD, PhD, Director of the Nat... |
| 05.08.2024 | SITC Announces 2024 Class of Fellows to the Academy of Immuno-Oncology | Academy of Immuno-Oncology
The Society for Immunotherapy of Cancer (SITC) announces the 2024 Class of Fellows of the Academy of Immuno-Oncology (FAIO). The luminaries of the 2024 class will be inducted at an event during SITC's 39th Annual ... |
| 22.07.2024 | Society for Immunotherapy of Cancer Announces Annual Award Recipients | Society for Immunotherapy of Cancer logo
The Society for Immunotherapy of Cancer (SITC) honors notable contributors to the cancer immunotherapy field each year. SITC is thrilled to announce its 2024 Annual Awards recipients who will be hono... |
| 24.06.2024 | SITC Publishes First Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy | Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision Manuscript
A new manuscript series – The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cance... |
| 11.06.2024 | SITC Announces Keynote Speaker Dr. Ignacio Melero at the Immuno-oncology Drug Development Summit | SITC IO Drug Development Keynote Speaker
The Society for Immunotherapy of Cancer (SITC) is excited to announce that Ignacio Melero, MD, PhD from the Clinica Universidad de Navarra Medical School and Cima will present his keynote on Cancer I... |
| 15.05.2024 | SITC Announces Keynote Speakers Dr. Rafi Ahmed and Dr. Elizabeth M. Jaffee at its 39th Annual Meeting | SITC 2024 logo
The Society for Immunotherapy of Cancer (SITC) is excited to announce Rafi Ahmed, PhD, FAIO from the Emory University School of Medicine as the Keynote Speaker at its 39th Annual Meeting and Pre-Conference Programs (SITC 2024... |
| 23.04.2024 | Society for Immunotherapy of Cancer Publishes Recommendations on Optimal Intratumoral Immunotherapy Clinical Trial (IICT) Design | Society for Immunotherapy of Cancer Logo
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript "Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherap... |
| 12.04.2024 | SITC and the NCI Announce Fourth Year of Collaboration with the New AI in IO: Computational Immuno-oncology Webinar Series | AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series
The Society for Immunotherapy of Cancer (SITC), the world's leading member-driven organization dedicated to improving patient outcomes by advancing the science and application ... |
| 20.03.2024 | Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study | ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology in the United States
The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary effica... |
| 12.03.2024 | Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types | - |
| 08.09.2023 | Adagene to Present at Investor and Scientific Conferences in September | - Adagene's CEO and President of R&D, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies -
SAN DIEGO and SUZHOU, China, Sept. 8, 2023 /PRNewswire/ -- Adagen... |
| 15.06.2023 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Gynecologic Cancer | Immunotherapy is a rapidly evolving field. This guideline provides clinicians with trusted and up-to-date information with expert guidance on the nuances of the approved immunotherapy regimens.
MILWAUKEE (PRWEB) June 15, 2023
The Society fo... |
| 12.06.2023 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Gastrointestinal Cancer | Immunotherapy has transformed the standard of care for many gastrointestinal cancers, improving treatment responses and offering some patients prolonged survival.
MILWAUKEE (PRWEB) June 12, 2023
The Society for Immunotherapy of Cancer (SITC... |
| 11.05.2023 | SITC Announces Keynote Speakers Dr. Susan Kaech and Dr. Robert D. Schreiber at its 38th Annual Meeting | SITC is proud to continue to bring together the best and brightest minds in cancer immunotherapy to further the science and educate the next generation of scientists and clinicians.
MILWAUKEE (PRWEB) May 11, 2023
The Society for Immunothera... |
| 17.03.2023 | Accelerating Clinical Trials Through AI-Enabled Precision Oncology | Marie E. Lamont, Global RWE Data Strategy, Access & Enablement at IQVIA and General Manager
The American Cancer Society’s Cancer Statistics 2023 report highlighted a few major accomplishments within oncology, such as decreased cancer mo... |
| 12.01.2023 | SITC Releases Executive Summary from the Crisis in Clinical Research Virtual Summit | Webinar banner
MILWAUKEE (PRWEB) January 12, 2023
On Aug. 17, 2022, the Society for Immunotherapy of Cancer (SITC) convened key oncology experts from academia, industry and government, including the FDA and NCI, to lead a national conversat... |
| 08.11.2022 | Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting | Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting
Berlin, Germany, 08 November, 2022 – Glycotope GmbH, a biotechnology company with a prop... |
| 03.11.2022 | The Society for Immunotherapy of Cancer to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting | MILWAUKEE (PRWEB) November 03, 2022
The Society for Immunotherapy of Cancer (SITC) invites you to attend the virtual press briefing of the society’s 37th Annual Meeting (SITC 2022) beginning at 11:30 a.m. EST on Tuesday, Nov. 8, 2022.
The a... |
| 02.11.2022 | Faron Announces Poster Presentation at SITC | Faron Announces Poster Presentation at SITC
Wed, Nov 02, 2022 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron or “Company”)
Faron Pharmaceuticals Announces Poster Presentation of Targeted Immunotherapy Bexmarilimab at Socie... |
| 02.11.2022 | Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 37th Annual Meeting | “SITC is excited to incorporate these abstracts into an already impressive group of abstracts. The late-breaking abstracts will round out the content offered at the 37th Annual Meeting and highlight more cutting-edge research and data,” sai... |
| 17.10.2022 | PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 | DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data o... |
| 13.10.2022 | Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercializati... |
| 05.10.2022 | Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting | SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations repor... |
| 05.10.2022 | Black and African American Professionals Discuss Barriers in Biomedical Field | “As an organization, SITC is acutely aware of our unique opportunity to elevate and support a diverse cancer research community. The experiences of these panelists are illustrative of the work yet to be done and the power mentors and member... |
| 05.10.2022 | Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting | Oral Presentation of C-144-01 Trial Cohorts 2 and 4
/EIN News/ -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer im... |
| 04.10.2022 | The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology | "This checklist provides investigators, and other key stakeholders, a roadmap to identify and prioritize phase III clinical trials that are likely to offer the greatest benefit to patients." said SITC President Patrick Hwu, MD
MIL... |
| 19.09.2022 | Where To Find The Real Crisis In Clinical Research? Follow The Money | getty |
| 30.08.2022 | Society for Immunotherapy of Cancer Announces Annual Award Recipients | Society for Immunotherapy of Cancer (SITC) “The Annual Awards shine a spotlight on individuals and their important work, which directly impacts patients and enhances the immuno-oncology field. SITC is pleased to showcase the 2022 recipients... |
| 26.08.2022 | Society for Immunotherapy of Cancer to Host Intensive Cancer Immunotherapy and Tumor Immunology Educational Program | The Cancer Immunotherapy Winter School provides attendees a comprehensive education in cancer immunotherapy for those already in the lab or the clinic.
MILWAULKEE (PRWEB) August 26, 2022
The Society for Immunotherapy of Cancer (SITC) is ple... |
| 12.08.2022 | Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards | Society for Immunotherapy of Cancer (SITC) “Together with the immense generosity of our supporters, SITC is honored to help young investigators realize their cancer immunotherapy research dreams. It is our hope that these young researchers ... |
| 03.08.2022 | Society for Immunotherapy of Cancer (SITC) Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Nonmelanoma Skin Cancer | Immunotherapy is a rapidly-evolving field and many clinicians have limited experience using these agents to treat the more rare NMSCs. SITC developed this CPG because clinicians need expert guidance to interpret the nuances in the available... |
| 14.07.2022 | SITC Announces 2022 Class of Fellows to the Academy of Immuno-Oncology | I look forward to commemorating the new class of Fellows this fall at the SITC Annual Meeting. These individuals are at the vanguard of immuno-oncology and SITC is honored to recognize the impact they have on the field.
MILWAUKEE (PRWEB) Ju... |
| 02.06.2022 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Lung Cancer and Mesothelioma | SITC Cancer Immunotherapy Guidelines logo SITC’s CPGs are recognized as the gold-standard information on the use of immunotherapy to offer improved outcomes for patients with cancer.
MILWAUKEE (PRWEB) June 02, 2022
The Society for Immunothe... |
| 19.05.2022 | SITC Announces Keynote Speaker Dr. Padmanee Sharma and Keynote Panel Honoring the Work of Dr. Zelig Esshar at its 37th Annual Meeting | SITC 2022 logo I am deeply humbled to honor Dr. Zelig Eshhar, one of the earliest pioneers of CAR T therapy, during the SITC Annual Meeting, and to be alongside my tremendously accomplished colleagues on the panel will be invigorating,
MILW... |
| 18.05.2022 | SITC's "Targets for Cancer IO: A Deep Dive Series" Offers In-Depth Presentations on Cancer Immunotherapy | Society from Immunotherapy of Cancer's Targets for Cancer IO: A Deep Dive Series Despite the massive growth in scientific meetings in our field, this series stands out in that each webinar is totally focused on one particular topic, rather ... |
| 10.05.2022 | SITC’s Steven A. Rosenberg Scholars Award: $150,000 in Funding for an Emerging Leader in Immuno-Oncology | Society for Immunotherapy of Cancer (SITC) “Through his lab at the NCI, Dr. Rosenberg has engaged with hundreds of scientists, both young and old,” said SITC President Patrick Hwu, MD, who worked with Dr. Rosenberg at the NIH. “He has focus... |
| 26.04.2022 | Cancer Researchers to Rock Buddy Guy’s Legends for One Night Only | The CheckPoints Rockin’ for a Cure Fundraiser at Buddy Guy's in Chicago “Inspiring the next generation of cancer immunotherapy researchers has always been one of SITC’s main priorities,” said SITC President Patrick Hwu, MD. “The Forward Fun... |
| 27.01.2022 | Society for Immunotherapy of Cancer to Host Virtual Leadership Institute Focusing on Professional Development of Women in Cancer Immunotherapy | SITC WIN Logo SITC remains committed to advancing the careers of talented and emerging women leaders who are dedicated to better outcomes for cancer patients. The long-lasting relationships they will develop and skills they will learn, will... |
| 13.01.2022 | SITC to Offer Program for Emerging Leaders in Cancer Immunotherapy Focused on Accelerating Professional Development and Innovative Collaborations | SITC continues its commitment to advancing the best science that promotes the best outcomes for patients. We have a responsibility and obligation to further the careers and promote to leadership positions the best and brightest in our profe... |
| 15.11.2021 | Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021 | -ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in checkpoint inhibitor resistant/relapsed models while mitigating liver toxicity risk, computational analysis adds support to dosing strategy
-ATG-... |
| 13.11.2021 | Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) an... |
| 12.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma | 7 of 16 (44%) patients achieved best overall response of partial response
Confirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up
14 of 16 (88%) patients demonstrated tumor decrease from baseline
Batiraxcept has b... |
| 12.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma - Form 8-K | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept
(AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma
7 of 16 (44%) patients achieved best overall response of part... |
| 12.11.2021 | Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting | 21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Conference Call and Webcast on Saturday, November 13 at 5:30pm ET
SAN CARLOS, Calif., and WASHINGTON, ... |
| 12.11.2021 | Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details - Form 6-K | Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts
for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
• Data from Phase IIb AIPAC, including final Overall Survival data, reported in a separate announcemen... |
| 10.11.2021 | PharmaMar announces abstract to be presented at SITC 2021 | PharmaMar announces abstract to be
presented at SITC 2021
Madrid, November 10th, 2021. - PharmaMar (MSE:PHM) has announced today that
the abstract (number 464) titled "Lurbinectedin in combination with
Atezolizumab for second line Exte... |
| 09.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for... | 3 of 5 (60%) patients achieved a partial response
All 5 patients treated demonstrated tumor decrease from baseline
Batiraxcept has been generally well-tolerated with no dose-limiting toxicities
Aravive to host conference call and webcast on... |
| 09.11.2021 | Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details | ASX/Media Release
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts
for SITC 2021 Annual Meeting & AIPAC Global Webcast Details
Data from Phase IIb AIPAC, including final Overall Survival data, reported in a sepa... |
| 09.11.2021 | BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSITIVE NSCLC AT SITC ANNUAL MEETING 2021 | BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL DATA ON BEMCENTINIB IN STK11-POSITIVE NSCLC AT SITC ANNUAL MEETING 2021 Tue, Nov 09, 2021 14:00 CET
Bergen, Norway, 9 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical... |
| 09.11.2021 | Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer | Final Overall Survival (OS) data supports Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancerOS benefit trend in total population, with median survival benefit of +2.9 months from efti plus chem... |
| 09.11.2021 | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to - Form 8-K | Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating
Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to
be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting
... |
| 09.11.2021 | Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting | TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer
21.4% Overall Response Rate (ORR) for TIL Therapy in Advanced, Immune Checkpoint Inhi... |
| 09.11.2021 | Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting | TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer
21.4% Overall Response Rate (ORR) for TIL Therapy in Advanced, Immune Checkpoint Inhi... |
| 05.11.2021 | ACGT Scientific Advisory Council Chair Michael T. Lotze, MD, Honored with Lifetime Achievement Award from Society for Immunotherapy of Cancer | Dr. Michael Lotze, ACGT Scientific Advisory chair & with University of Pittsburgh, is being awarded the prestigious SITC Lifetime Achievement Award
STAMFORD, Conn. (PRWEB) November 05, 2021
Alliance for Cancer Gene Therapy (ACGT) Scient... |
| 02.11.2021 | The Society for Immunotherapy of Cancer (SITC) invites you to attend the virtual press briefing of the society’s 36th Anniversary Annual Meeting | The Society for Immunotherapy of Cancer's (SITC) 36th Anniversary Annual Meeting (SITC 2021)
MILWAUKEE (PRWEB) November 02, 2021
The Society for Immunotherapy of Cancer (SITC) invites you to attend the virtual press briefing of the society’... |
| 01.11.2021 | Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 36th Annual Meeting | SITC is pleased to incorporate these abstracts into an already stellar schedule. The late-breaking abstracts will round out the content offered at the 36th Annual Meeting and highlight more recent data and research.
MILWAUKEE (PRWEB) Novemb... |
| 25.10.2021 | Society for Immunotherapy of Cancer Announces Annual Award Recipients | 2021 SITC Annual Awards Recipients SITC is proud to recognize these outstanding individuals from the cancer immunology and immunotherapy community. The Annual Awards represent the growing prestige of our society and our field thanks to the ... |
| 22.10.2021 | Society for Immunotherapy of Cancer Announces 2021 Medal of Honor Recipients | BioNTech cofounders Uğur Şahin, MD and Özlem Türeci, MD - recipients of the SITC Medal of Honor We all recognize the incredible contributions of Project Lightspeed to humanity, and we are honored to have them accept this medal and present a... |
| 15.10.2021 | SITC Announces Inaugural Class of Fellows to the Academy of Immuno-Oncology | 2021 Class: Fellows of the Academy of Immuno-Oncology
MILWAUKEE (PRWEB) October 15, 2021
The Society for Immunotherapy of Cancer (SITC) has announced the inaugural class of Fellows of the Academy of Immuno-Oncology (FAIO), which is one of t... |
| 06.10.2021 | Targovax ASA: Two abstracts accepted at the SITC Congress | Targovax ASA: Two abstracts accepted at the SITC Congress Wed, Oct 06, 2021 14:27 CET
Oslo, Norway, 6 October 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat sol... |
| 04.10.2021 | Tempest Therapeutics : Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting | SOUTH SAN FRANCISCO, Calif. - Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced the acceptanc... |
| 04.10.2021 | Affimed N : Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer | Heidelberg, Germany - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that three abstracts with preclinical data of its innate cell enga... |
| 01.10.2021 | Nkarta : to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting | Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development programs Update also highlights novel meth... |
| 01.10.2021 | BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021 | BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021 Fri, Oct 01, 2021 15:19 CET
Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company de... |
| 01.10.2021 | Tempest Therapeutics : Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting | SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated me... |
| 16.09.2021 | SITC Debuts Clinical Practice Guidelines Mobile App Focused on Immunotherapy | Cancer Immunotherapy Clinical Practice Guidelines Mobile App Screen Shots “The SITC CPG Mobile App will be a valuable resource for cancer care providers, by providing guideline information and interactive tools to help design and carry out ... |
| 14.09.2021 | SITC and AACR Outline Future Directions for Investigating Immune-related Adverse Events | “Just as SITC and AACR partnered to establish these recommendations, so too will multidisciplinary collaborations be critical to answering these important questions.”
MILWAUKEE (PRWEB) September 14, 2021
The Society for Immunotherapy of Can... |
| 10.08.2021 | Society for Immunotherapy of Cancer Forward Fund Announces Recipients of 2021 Postdoctoral Cancer Immunotherapy Fellowships and Awards | “These investments enable research in critical areas of immunology by early career investigators and leaders to hopefully bring ground-breaking therapies to those fighting cancer," said SITC President Patrick Hwu, MD.
MILWAUKEE (PRWEB)... |
| 05.08.2021 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Urothelial Cancer | SITC Cancer Immunotherapy Guidelines logo “Immunotherapy fills an important unmet need for patients with urothelial cancer who are too frail or are unwilling to endure the toxicity associated with chemotherapy,” said Matthew D. Galsky, co-c... |
| 14.06.2021 | $150,000 in Funding for an Emerging Leader in Immuno-Oncology: SITC’s Steven A. Rosenberg, MD, PhD, Scholars Award | Society for Immunotherapy of Cancer (SITC) “Through his lab at the NCI, Dr. Rosenberg has engaged with hundreds of scientists, both young and old,” said SITC President Patrick Hwu, MD, who worked with Dr. Rosenberg at the NIH. “He has focus... |
| 27.05.2021 | SITC to Offer Program for Emerging Leaders in Cancer Immunotherapy Focused on Accelerating Professional Development and Innovative Collaborations | SITC Sparkathon Accelerator “SITC is committed to advancing the best science and promote the best outcomes for patients, so we have a responsibility and obligation to further the careers and promote to leadership positions the best and brig... |
| 19.04.2021 | Society for Immunotherapy of Cancer Launches Online Seminar Series on Advanced Topics in Immuno-Oncology | Society for Immunotherapy of Cancer (SITC) “Many immunotherapy approaches have gained FDA approval in the last ten years; however, the majority of these approvals are for immune checkpoint inhibitors targeting the PD-(L)1 or CTLA-4 pathways... |
| 14.04.2021 | SITC to Host Fundamental Two-Day Workshop Focused on Cytokines in Cancer Immunotherapy | Society for Immunotherapy of Cancer (SITC) “Cytokines impact every aspect of cancer immunotherapy; however, many important questions are outstanding in our understanding of the impact of cytokines on immune cells,” said SITC President Patri... |
| 07.04.2021 | Society for Immunotherapy of Cancer to Host Back-to-Back Workshops on Tumor Cell Surfaceome and Bispecific T cell Engagers | Society for Immunotherapy of Cancer “SITC is continually developing educational and networking opportunities to create a lasting impact on clinical practice by highlighting emerging topics relevant to immuno-oncology,” said SITC President P... |
| 01.04.2021 | SITC Announces Two Spatial Technology Awards for Early Career Scientists to Advance Cancer Immunotherapy Research | Society for Immunotherapy of Cancer “SITC views these two unique technology awards as an investment in the future of our field that we hope will lead to innovative and cutting-edge immunotherapy approaches and ultimately better outcomes for... |
| 04.03.2021 | Society for Immunotherapy of Cancer to Host Virtual Leadership Institute Focusing on Professional Development of Women in Cancer Immunotherapy | Society for Immunotherapy of Cancer (SITC) “During my term as our society’s first female President, one of my primary goals was highlighting and supporting the contributions women have made, and continue to make, in cancer immunotherapy and... |
| 10.02.2021 | Society for Immunotherapy of Cancer Announces $450,000 in Cancer Immunotherapy Fellowships for Early Career Scientists | Society for Immunotherapy of Cancer “SITC is able to support up-and-coming leaders within the cancer immunotherapy field who are conducting promising research, thanks to the generosity of our industry partners,” said SITC President Patrick ... |
| 07.01.2021 | Society for Immunotherapy of Cancer Publishes Clinical Immunotherapy Treatment Guidelines for Lymphoma | “I believe the publications containing our society’s Cancer Immunotherapy Guidelines program are an important resource for clinicians as the number and complexity of treatments increase across the entire spectrum of malignancies,” said SITC... |
| 18.12.2020 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immune Effector Cell-related Adverse Events | “This is the tenth manuscript published in SITC’s Cancer Immunotherapy Guidelines series, a critically important effort to educate physicians and other health care providers, and improve outcomes for cancer patients receiving FDA-approved i... |
| 08.11.2019 | Forbius Completes Phase 1 Oncology Dose Escalation with AVID200 | Austin, TX, and Montreal, QC (Nov. 8, 2019) – Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, today presented the first Phase 1 clinical data from its oncology development pr... |
| 18.04.2015 | San Diego biotech Glycoregimmune raises $4.3 million for natural killer T cell-based therapy | The immunotherapy biotech just raised $4.3 million, according to a regulatory filing. The research comes from Torrey Pines Institute for Molecular Studies.
Its lead program, the oral drug GRI-0621, is in the midst of early clinical studies ... |
| - | Carisma Therapeutics Presents Data from Phase I Clinical Trial of CT-0508, A HER2 Targeted CAR-Macrophage | PHILADELPHIA, November 12, 2021, 12:10 PM ET— Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today for the first time preliminary findings fr... |
| - | San Diego biotech Glycoregimmune raises $4.3 million for natural killer T cell-based therapy | San Diego biotech Glycoregimmune is working on a way to inhibit the natural killer T cells that exacerbate the inflammatory response and hepatic injury that stems from liver disease.
Natural killer T cells are a sort of heterogenous variety... |
